MRT-2359 free base · Synonyms: MRT 2359 · MRT2359

MRT-2359 is an orally active and potent degrader of GSPT1 with anti-tumor activity.

For research use only. Not for human or veterinary use.

Target Molecular Glues Apoptosis

Research area Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

MRT-2359 structure

CAS No.: 2803881-11-8

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 550.00	BP-02370-50mg	In stock	Get quote
100 mg	USD 785.00	BP-02370-100mg	In stock	Get quote
250 mg	USD 1,285.00	BP-02370-250mg	In stock	Get quote
500 mg	USD 1,885.00	BP-02370-500mg	In stock	Get quote
1 g	USD 2,685.00	BP-02370-1g	In stock	Get quote
2 g	Inquire	BP-02370-2g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

MRT-2359 is an orally active and potent degrader of GSPT1 with anti-tumor activity. MRT-2359 also inhibits the growth of resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells. MRT-2359 exhibits preferential activity in MYC-driven cell lines, such as N- and L-MYC high NSCLC and SCLC patient-derived xenografts (PDXs).

Biological activity

MRT-2359 is an orally active and potent degrader of GSPT1 with anti-tumor activity.

Identifiers

SMILES: O=C(NC1=CC(OC(F)(F)F)=CC=C1F)OCC2=CC=C3C(C(N(C4C(NC(CC4)=O)=O)C3)=O)=C2
InChIKey: HNTGMIGBGVFOBT-UHFFFAOYSA-N

Specifications

MW (average): 495.3805
Formula: C₂₂H₁₇F₄N₃O₆
CAS No.: 2803881-11-8
Physical state: Solid
Color: white to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO

In vitro: DMSO : 100 mg/mL

Documents

References

[1]. Gerald Gavory, et al. Identification of MRT-2359, a Potent, Selective and Orally Bioavailable GSPT1-directed Molecular Glue Degrader (MGD) for the Treatment of Cancers with MYC-induced Translational Addiction.

[2]. Gerald Gavory, et al. Abstract 3449: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction. Cancer Res (2023) 83 (7_Supplement): 3449.

[3]. Gerald Gavory, et al. Abstract 3929: Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction. Cancer Res (2022) 82 (12_Supplement): 3929.

[4]. Ralph Tiedt, et al. Abstract 3294: The GSPT1 molecular glue degrader MRT-2359 is active against prostate cancer. Cancer Res (2024) 84 (6_Supplement): 3294.

[5]. Chang X, et al. Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective. Med Res Rev. 2024 Jul;44(4):1727-1767.

Same target

Search Molecular Glues

Same research area

Search Inflammation/Immunology